Formulary Search Results for: DARBEPOETIN ALFA
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias - View Category
Restrictions:
Restricted to specialist initiation. Approved in NHSGGC only for anaemia associated with renal failure. This is the preferred Formulary agent for this indication.
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias - View Category
Restrictions:
Restricted to specialist initiation. Approved in NHSGGC only for anaemia associated with renal failure.
Prescribing Notes:
- Prescribe by brand name.
- The treatment of symptomatic anaemia in adults with low or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoetin is not recommended for use by the SMC and is non-Formulary.
9.6.4 Vitamin D - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Not suitable for treatment of vitamin D deficiency.
9.8.1 Drugs used in metabolic disorders - View Category
Restrictions:
Restricted to specialist use as an enzyme-replacing therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency).
9.8.1 Drugs used in metabolic disorders - View Category
Restrictions:
Restricted to specialist use only as a long-term enzyme replacement therapy in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency).
3.4.3 Allergic emergencies - View Category
Restrictions:
Treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency is restricted to specialist use only.
3.7 Mucolytics - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Responsibility for initiation, review and any necessary monitoring rests with specialist service.
9.8.1 Drugs used in metabolic disorders - View Category
Restrictions:
Restricted to specialist use only.
Prescribing Notes:
As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.
Designated as an ultra-orphan drug. Appropriate paperwork needs completing before prescribing to ensure registration on the national risk sharing scheme.
6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens - View Category
6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens - View Category
Restrictions:
Restricted to specialist use for the indications listed in the Prescribing Notes section below:
Prescribing Notes:
In adult women for:
- anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate.
- stimulation of multi-follicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intrafallopian transfer and zygote intra-fallopian transfer.
- in association with a luteinising hormone (LH) preparation for the stimulation of follicular development in women with severe LH and follicle-stimulating hormone (FSH) deficiency. In clinical trials these patients were defined by an endogenous serum LH level <1.2 units/L.
In adult men for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hCG) therapy.
The BNF recommends that is is good practice to prescribe biosimilars by brand name.